NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws.
If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.
Why Did DexCom’s Stock Drop?
DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force restructuring was paying dividends and how GLP-1 weight loss drugs were complimentary to DexCom’s products.
After the market closed on July 25, 2024, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. The company attributed the results to challenges it had encountered restructuring its sales force, but at least one analyst questioned whether the surging popularity of GLP-1 treatments had an impact.
The news caused a precipitous decline in the price of DexCom stock. The price of the company’s stock closed at $107.85 per share on July 25, 2024. Prior to the market open on July 26, 2024, DexCom stock was trading in the range of $66.60 per share, a decline of $41.25 per share, or 38%.
Click here for more information: https://www.bfalaw.com/cases-investigations/dexcom-inc.
What Can You Do?
If you invested in DexCom, Inc. you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/dexcom-inc
Or contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/dexcom-inc
Attorney advertising. Past results do not guarantee future outcomes.
- URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN) - June 8, 2025
- TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - June 7, 2025
- Tulip Real Estate Acquires Premier London Hilton Property in £30 Million Deal from Lone Star - June 7, 2025
